Advertisement

Product › Details
Zynlonta™
![]() |
Next higher product group | loncastuximab tesirine-lpyl (ADCT-402) |
![]() |
Status | 2021-04-23 registration start |
![]() |
Organisation | ADC Therapeutics S.A. (NYSE: ADCT) |
Group | ADC Therapeutics (Group) | |
![]() |
Source | ADC Therapeutics S.A.. (8/3/21). "Press Release: ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates". Lausanne. |
Record changed: 2023-07-23 |
Advertisement

More documents for Zynlonta™
- [1] ADC Therapeutics S.A.. (7/20/23). "Press Release: ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients". Lausanne....
- [2] ADC Therapeutics S.A.. (1/4/23). "Press Release: ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference". Lausanne....
- [3] ADC Therapeutics S.A.. (12/21/22). "Press Release: ADC Therapeutics and Sobi Announce European Commission Approval of Zynlonta (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma". Lausanne....
- [4] ADC Therapeutics S.A.. (11/1/22). "Press Release: ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer". Lausanne....
- [5] ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne....
- [6] ADC Therapeutics S.A.. (7/1/22). "Press Release: ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors". Lausanne....
- [7] ADC Therapeutics S.A.. (6/29/22). "Press Release: ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents". Lausanne....
- [8] ADC Therapeutics S.A.. (6/13/22). "Press Release: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer". Lausanne....
- [9] ADC Therapeutics S.A.. (5/9/22). "Press Release: ADC Therapeutics Announces CEO Transition. Co-Founder Chris Martin Transitions CEO Role to Industry Veteran Ameet Mallik". Lausanne....
- [10] ADC Therapeutics S.A.. (1/18/22). "Press Release: ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta(loncastuximab tesirine-lpyl) in Japan". Lausanne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top